Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00550446 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 386
- Enrollment target
NCT00550446: Completed Phase 2 study, sponsored by Pfizer.
NCT00550446 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 386 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (190% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00550446, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 386 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)
Primary Outcome
ACR20 response: greater than or equal to (\>=) 20 % improvement in tender joint count (TJC); \>= 20% improvement in swollen joint count (SJC); and \>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-Reactive Protein (CRP).
Interventions
- DRUG Adalimumab
- DRUG CP-690,550
- DRUG CP-690-550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 386 participants |
| Start Date | 2007-09 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
What the finished NCT00550446 record still lists
NCT00550446 is an interventional study that assigns participants to a tested intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (190% higher).
The record links to 0 conditions, and to 3 interventions - of which Adalimumab is the first listed.
NCT00550446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00550446 about?
NCT00550446 is a clinical study titled "A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis". The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven wi...
What is the current status of trial NCT00550446?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 386 participants. The study started on 2007-09. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00550446?
The interventions under investigation include: Adalimumab (DRUG), CP-690,550 (DRUG), CP-690-550 (DRUG).
Who is sponsoring clinical trial NCT00550446?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00550446's enrollment target sits among peer trials
386 109th of 2000 higher than 1,892 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05645107 · 386 participants · Phase 3
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- NCT05896189 · 386 participants · NA
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
- NCT06686121 · 386 participants · Phase 3
Improving Mobility After Revascularization in Peripheral Artery Disease
- NCT07424547 · 386 participants · Phase 1
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia